Filing Details
- Accession Number:
- 0001209191-17-050586
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-08-29 17:30:04
- Reporting Period:
- 2017-08-28
- Accepted Time:
- 2017-08-29 16:30:04
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1515673 | Ultragenyx Pharmaceutical Inc. | RARE | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1248093 | D Emil Kakkis | C/O Ultragenyx Pharmaceutical Inc. 60 Leveroni Court Novato CA 94949 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-08-28 | 5,853 | $52.40 | 2,558,094 | No | 4 | P | Indirect | By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 |
| Common Stock | Acquisiton | 2017-08-28 | 1,647 | $52.96 | 2,559,741 | No | 4 | P | Indirect | By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 |
| No | 4 | P | Indirect | By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 430,569 | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $51.89 to $52.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $52.90 to $52.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Billionaire Hedge Funds
